Zacks: Analysts Expect Urogen Pharma Ltd (URGN) Will Announce Earnings of -$1.08 Per Share

Wall Street brokerages expect Urogen Pharma Ltd (NASDAQ:URGN) to post earnings per share of ($1.08) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Urogen Pharma’s earnings, with the lowest EPS estimate coming in at ($1.14) and the highest estimate coming in at ($1.02). Urogen Pharma posted earnings per share of ($0.02) in the same quarter last year, which would suggest a negative year over year growth rate of 5,300%. The company is scheduled to report its next quarterly earnings report on Tuesday, November 13th.

According to Zacks, analysts expect that Urogen Pharma will report full year earnings of ($4.12) per share for the current financial year, with EPS estimates ranging from ($4.32) to ($3.89). For the next year, analysts anticipate that the firm will report earnings of ($4.93) per share, with EPS estimates ranging from ($6.71) to ($3.47). Zacks’ EPS calculations are an average based on a survey of research firms that that provide coverage for Urogen Pharma.

Urogen Pharma (NASDAQ:URGN) last released its quarterly earnings results on Tuesday, August 14th. The company reported ($1.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.25). The business had revenue of $0.36 million for the quarter. Urogen Pharma had a negative return on equity of 44.24% and a negative net margin of 470.54%.

A number of research firms have recently weighed in on URGN. Stifel Nicolaus began coverage on Urogen Pharma in a report on Thursday, September 13th. They set a “buy” rating and a $70.00 price target for the company. Oppenheimer set a $75.00 price target on Urogen Pharma and gave the stock a “buy” rating in a report on Tuesday, August 14th. Cowen reiterated a “buy” rating on shares of Urogen Pharma in a report on Tuesday, August 14th. Finally, ValuEngine upgraded Urogen Pharma from a “hold” rating to a “buy” rating in a report on Saturday, June 2nd. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $59.60.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Harel Insurance Investments & Financial Services Ltd. purchased a new position in Urogen Pharma during the 2nd quarter valued at about $129,000. Quantbot Technologies LP purchased a new position in Urogen Pharma during the 1st quarter valued at about $174,000. UBS Group AG boosted its holdings in Urogen Pharma by 31.5% during the 1st quarter. UBS Group AG now owns 3,611 shares of the company’s stock valued at $180,000 after acquiring an additional 865 shares during the period. DAFNA Capital Management LLC purchased a new position in Urogen Pharma during the 1st quarter valued at about $224,000. Finally, Jane Street Group LLC purchased a new position in Urogen Pharma during the 2nd quarter valued at about $227,000. Institutional investors and hedge funds own 71.11% of the company’s stock.

Shares of NASDAQ URGN traded down $0.12 during mid-day trading on Tuesday, reaching $48.90. 30,500 shares of the company’s stock were exchanged, compared to its average volume of 113,268. The stock has a market cap of $681.11 million, a PE ratio of -22.85 and a beta of 2.01. Urogen Pharma has a 52-week low of $25.56 and a 52-week high of $69.57.

Urogen Pharma Company Profile

UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. Its lead product candidates, MitoGel and VesiGel are proprietary formulations of the chemotherapy drug Mitomycin C, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy.

See Also: Trading Penny Stocks

Get a free copy of the Zacks research report on Urogen Pharma (URGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Urogen Pharma (NASDAQ:URGN)

Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply